• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    3.850 -0.030 (-0.77%)
    Streaming Delayed Price Updated: 12:53 PM EDT, Jun 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,699,767
    Open 3.850
    Bid (Size) 3.850 (1,000)
    Ask (Size) 3.860 (3,900)
    Prev. Close 3.880
    Today's Range 3.830 - 4.060
    52wk Range 1.660 - 5.630
    Shares Outstanding 305,252,194
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
    From Biotech Insider
    Via GlobeNewswire
    News headline image
    Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +52.8%
    +52.8%
    1 Month
    +4.1%
    +4.1%
    3 Month
    -26.0%
    -26.0%
    6 Month
    +71.1%
    +71.1%
    1 Year
    +74.2%
    +74.2%

    More News

    Read More
    News headline image
    Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For? ↗
    Via The Motley Fool
    BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market ↗
    Via Chartmill
    Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
    Via Chartmill
    How Advanced Drug Delivery Could Improve Existing Cancer Treatments
    Via Investor Brand Network
    News headline image
    How Advanced Drug Delivery Could Improve Existing Cancer Treatments
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance Biotherapeutics to Present at Upcoming Conference
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Iovance (IOVA) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street ↗
    Via The Motley Fool
    Topics Death
    News headline image
    Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare? ↗
    Via The Motley Fool
    News headline image
    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
    Via MarketBeat
    News headline image
    Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
    Via The Motley Fool
    News headline image
    IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
    Via Stocktwits
    News headline image
    Iovance Biotherapeutics to Present at Upcoming Conferences
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
    Via Stocktwits
    Topics Earnings
    Curious about the most active stocks on Tuesday? ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings

    Frequently Asked Questions

    Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
    Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
    What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
    The current price of Iovance Biotherapeutics, Inc. - Common Stock is 3.850
    When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 06/10/26 12:53 PM ET
    What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
    The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 1.18B
    How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
    Iovance Biotherapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.